NCBP2 and cancer: As shown in Fig. 1D, the general alteration frequency of NCBP2 was relatively high in the top five cancers, which had an alteration frequency of >20% with “Amplification” as the primary type, while the most frequent NCBP2 alteration was identified among LUSC patients (>40%).